Dangerous Diabetes Drugs
With more than 25.8 million people in the United States suffering from diabetes, drug companies are always looking to increase their profits by introducing new Type 2 Diabetes treatments. By providing new treatment options for this ever-growing segment of the population, drug companies hope to hit the latest blockbuster drug.
Unfortunately, a new class of Type 2 Diabetes treatment called incretin mimetics, many of which have turned out to be blockbusters, have also turned out to carry risks of serious side effects such as pancreatitis, pancreatic cancer, and thyroid cancer. Drugs in this class include Januvia, Byetta, Victoza, Onglyza, Tradjenta, and others.
Individuals that have been injured by these drugs are joining lawsuits to receive compensation for their injuries. Contact us today to see if you qualify to join.
Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen stated that the pharmaceutical company is looking into continuing trials to determine if Victoza could be marketed as a possible Alzheimer’s treatment. Victoza is currently going through a proof of concept study. If this is successful, the drug will continue through phase III clinical trials to see…
Merck, manufacturer of the controversial diabetes drug Januvia, has made the decision to stop manufacturing a combination of Januvia (sitagliptin) and the high cholesterol treatment simvastatin. The drug was called Juvisync, and the theory behind it was that the company could increase profits by capitalizing on the large population of individuals that suffer from high…
In Maryland, a jury found drug giant Takeda Pharmaceutical Company liable for $1.7 million in damages for not properly warning its user regarding the risks of taking Actos and developing bladder cancer or heart problems. The subject of the case was a deceased man by the name of Diep An, who was a former U.S….